Trial reportNature communications2018
Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers.
Trial report in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Phase 1 Study of LGW16-03 To Identify Nerves
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic accuracy and surgical outcomes of fluorescence-guided surgery in breast cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- Fluorescence guided surgery imaging systems for breast cancer identification: a systematic review.Journal of biomedical optics · 2024Pooled it
- Pooled it
- Near-infrared fluorescence imaging-guided surgery using cRGD-ZW800 to improve surgical resection margins in oral cancer: a phase I/II feasibility trial.Nature communications · 2026Trial
- Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- A pH/ATP Dual-Sensitive Nanoprobe-Based Bioluminescence Imaging for Intraoperative Human Multicancer Detection.Chemical & biomedical imaging · 2026Article
- Clinical fluorescent probes: mechanisms, advantages and inspirations.Chemical science · 2026Review
- Article
- Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery.Journal of clinical medicine · 2026Review
- Intraoperative measurement of breast-conserving surgery margins: surgical application.Breast cancer research : BCR · 2026Review
- Real-time fidelity assessment of fluorescence molecular imaging without reference images.Journal of biomedical optics · 2026Article
- Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles.Npj imaging · 2026Article
- Margin status after breast-conserving surgery for breast cancer in the Netherlands from 2009 to 2022.BJS open · 2026Article
- Standardizing clinical trials in near-infrared fluorescence imaging: a workflow and regulatory framework proposal.Npj imaging · 2026Review
- Synthesis and preclinical evaluation of FAP-targeting radiotracers for PET and optical imaging.EJNMMI radiopharmacy and chemistry · 2025Article
- Reflect: reporting guidelines for preclinical, translational and clinical fluorescence molecular imaging studies.Npj imaging · 2025Article
- Aptamer-based NIR II imaging for breast cancer surgical resection.Npj imaging · 2025Article
- Tumor microenvironment responsive Mn-based nanoplatform activate cGAS-STING pathway combined with metabolic interference for enhanced anti-tumor therapy.Journal of nanobiotechnology · 2025Article
- GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.Breast cancer research and treatment · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.